DoseSpot evaluated whether each prescription was eligible for additional savings from a different pharmacy or through manufacturer cost-saving programs, and whether receiving the medication directly from a manufacturer (which often is less expensive) was an option. A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential cost savings that is easily in the billions of dollars, the company said.

One reason why these findings are significant is that a recent national survey found that one-third of American don't fill their prescriptions -- and the top reason is cost. GLP-1 adherence is especially low at just 46.3% at 180 days. Savings programs are a critical component of medication adherence, not just for onetime use but on a recurring basis. With compounded GLP-1s exiting the market, it’s especially important for patients to explore cost savings in other ways so they can continue taking weight-loss medications, DoseSpot CEO Josh Weiner said.

“Regardless of their insurance status, the vast majority of patients are still unaware of cost-saving programs,” he said. “Patients need to do their homework. A quick online search for these programs can yield significant savings. Patients also need to speak with providers about pharmacy pricing and dispensing options. Providers can access these details, but most don’t share it proactively -- you need to ask.”